• Andrea M Lerner, Robert W Eisinger, Douglas R Lowy, Lyle R Petersen, Rosemary Humes, Matthew Hepburn, and M Cristina Cassetti.
• Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: andrea.lerner@nih.gov.
• Immunity. 2020 Jul 14; 53 (1): 1-5.

AbstractThe development, validation, and appropriate application of serological assays to detect antibodies to SARS-CoV-2 are essential to determining seroprevalence of this virus in the United States and globally and in guiding government leadership and the private sector on back-to-work policies. An interagency working group of the US Department of Health and Human Services convened a virtual workshop to identify knowledge gaps and key outstanding scientific issues and to develop strategies to fill them. Key outcomes of the workshop included recommendations for (1) advancing serology assays as a tool to better understand SARS-CoV-2 infection and (2) conducting crucial serology field studies to advance an understanding of immunity to SARS-CoV-2, leading to protection and duration of protection, including the correlation between serological test results and risk of reinfection.Copyright © 2020.

17 keywords...

hide…